Understanding Anti-Nuclear Antibodies and Their Role in Autoimmune Disease Screening
Samwel Mikaye, Chief Executive Officer at Samik Medical Center, shared in the Laboratory Professionals International group on LinkedIn:
”Anti-Nuclear Antibody (ANA)
What Are They?
Anti-nuclear antibodies (ANA) are autoantibodies produced by the immune system that mistakenly attack the nucleus of the body’s own cells. The nucleus contains DNA, RNA, and associated proteins, so ANA may target these nuclear components, including nucleotides.
Why Are ANA Tested?
The ANA test is mainly used to screen for autoimmune diseases, especially:
• Systemic Lupus Erythematosus (SLE) — most commonly associated
• Sjögren’s Syndrome
• Scleroderma (Systemic Sclerosis)
• Mixed Connective Tissue Disease
• Autoimmune Thyroid Disorders (sometimes)
• Rheumatoid Arthritis (occasionally)
How Is the Test Reported?
• Results are given as titers, such as 1:40, 1:160, or 1:320.
• A higher titer suggests stronger autoimmune activity.
• The pattern seen in the lab (e.g., homogeneous, speckled, nucleolar, or centromere) may help indicate which autoimmune condition is more likely — but pattern alone is not diagnostic.
Important Interpretation Notes
• A positive ANA does not always mean disease.
• Many healthy individuals, especially elderly or those with infections, may have low-level ANA positivity.
• A negative ANA makes lupus very unlikely, but does not completely rule out all autoimmune disorders.
• Additional specific antibody tests (like anti-dsDNA, anti-Smith, anti-Ro/La) are often required to confirm diagnosis.
Key Takeaways
- ANA are antibodies that react against the body’s own cell nuclei
- Used mainly as a screening tool for autoimmune diseases like lupus
- Positive ANA alone is not enough for diagnosis — symptoms and further tests are essential
- Negative ANA reduces likelihood of lupus significantly.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch
-
Feb 23, 2026, 16:36Stéphanie Roullet։ New Method to Explore Primary Haemostasis in Cirrhotic Patients
-
Feb 23, 2026, 16:33Salvatore Massimo Petrina: Top 5 Game-Changers in the AHA and ACC PE Guidelines
-
Feb 23, 2026, 16:21Azin Alizadehasl: Introducing the Second Edition of a New Book on Echocardiography and Cardiac MRI
-
Feb 23, 2026, 16:16Kalyan Roy: When and Why Blood Irradiation Matters in Transfusion Medicine
-
Feb 23, 2026, 15:59Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update
-
Feb 23, 2026, 15:54Alan Nurden: From Early Discoveries to New Therapeutic Advances in von Willebrand Disease
-
Feb 23, 2026, 15:52Gevorg Tamamyan: Albania’s Vision for the Future of Pediatric Oncology
-
Feb 23, 2026, 15:36Simon Senanu: The Peripheral Blood Smear as an Essential Diagnostic Tool in Modern Medicine